drugset / Trial / NCT00236015

A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

NCT00236015

Phase 3 Completed 880 enrolled Cephalon
RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).

Timeline

Start
2004-11
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiagabine Small molecule 4 mg
Subject Tiagabine Small molecule 8 mg
Subject Tiagabine Small molecule 12 mg

Indications